Oryzon Genomics (ORY.MC)

Oryzon Genomics stock price today, ATLAS forecast and fair value

Healthcare · Biotechnology · Bolsa de Madrid (BME) · Spain

€2.50▲ 0.00%

Prices as of Oct 26, 2026 · EUR

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

51%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Oryzon Genomics in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Oryzon Genomics

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Oryzon Genomics a 51% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between €2.38 and €2.64; in 9 out of 10, between €2.18 and €2.88. Estimated annual volatility is 20%.

Price, last 12 months (weekly close)

Key numbers

Market cap: €207M
Market cap (USD): $232M
52-week high: €3.75
52-week low: €2.48
Revenue (12 months): €15.4M
Gross margin: 97.8%
Operating margin: 30.8%
Net margin: -15.8%
Beta: 0.40

What this means

ATLAS does not publish a fair value for ORY.MC right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks ORY.MC has traded between €2.48 and €3.75. Today it is 33.2% below that high and 1% above its low.

Its beta is 0.40: it tends to move less than the market.

About the company

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.

Want to see everything about Oryzon Genomics?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Oryzon Genomics do?

What is the chance ORY.MC goes up next month?

51%: close to a coin flip. In half of the simulated outcomes, ORY.MC ends the month between €2.38 and €2.64.

How big is Oryzon Genomics and what is its P/E ratio?

Oryzon Genomics's market capitalization is €207M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is ORY.MC?

ATLAS estimates annual volatility at 20%. In a typical month, half of the outcomes end between €2.38 and €2.64.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer